Clopidogrel Tablet
Product Images NDC 50090-7467

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 50090-7467). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clop02-a (Clop02 A)

A horizontal error bar chart showing the effect of co-administered proton pump inhibitors (PPIs) on the active metabolite AUC of clopidogrel. The chart compares dexlansoprazole 60 mg, lansoprazole 30 mg, pantoprazole 80 mg, and omeprazole 80 mg, plotting their mean values and 90% confidence intervals relative to Plavix administered alone, with a range from 0.4 to 1.4 on the x-axis representing the change in active metabolite exposure.*

FDA Label Image

Clop03-a (Clop03 A)

A line graph showing cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. Two lines compare patients treated with placebo plus aspirin versus clopidogrel plus aspirin, indicating lower event rates for clopidogrel. The x-axis represents months of follow-up, and the y-axis shows cumulative event rate percentage.*

FDA Label Image

Clop04-a (Clop04 A)

A forest plot chart displaying hazard ratios with 95% confidence intervals for various subgroups comparing Clopidogrel versus placebo. Subgroups include age, gender, race, diabetes status, previous conditions, and medication use, illustrating the effect trend favoring Clopidogrel in most categories.*

FDA Label Image

Clop08-a (Clop08 A)

A line graph showing cumulative event rates (%) of fatal or non-fatal vascular events over 36 months of follow-up for two treatments: aspirin and clopidogrel. The graph plots event rates on the vertical axis against months on the horizontal axis, with clopidogrel showing a slightly lower cumulative event rate than aspirin. A p-value of 0.045 is indicated.*

FDA Label Image

Clop_01 (Clop 01)

Chemical structure of clopidogrel bisulfate, showing the molecular arrangement of atoms including a chlorophenyl group, a thienopyridine ring system, and a methyl ester moiety with sulfate salt indicated.*

FDA Label Image

Clop_05 (Clop 05)

A Kaplan-Meier survival curve comparing the percentage of deaths before first discharge between patients receiving Clopidogrel tablets and placebo over up to 28 days since randomization. The graph shows cumulative mortality percentages on the y-axis and days since randomization on the x-axis, with annotations of total deaths and proportional risk reduction.*

FDA Label Image

Clop_06 (Clop 06)

A Kaplan-Meier curve graph showing the percentage of patients with death, reinfarction, or stroke before first discharge over 28 days since randomization. It compares Clopidogrel tablets to placebo, with the placebo group showing 10.1% events and Clopidogrel group showing 9.2%, indicating a 9% proportional risk reduction. A note states all treated patients received aspirin.*

FDA Label Image

Clop_07 (Clop 07)

A forest plot chart displaying subgroup analysis results comparing Clopidogrel Tablets 75 mg to placebo across various demographics and clinical categories. Subgroups include gender, age at entry, hours since onset, systolic blood pressure ranges, heart rate ranges, and fibrinolytic agent use, with odds ratios and 95% confidence intervals shown to evaluate treatment effect favoring Clopidogrel or placebo.*

FDA Label Image

Clop_09 (Clop 09)

A hazard ratio forest plot comparing Clopidogrel Tablets and Aspirin across qualifying conditions: Stroke, MI, PAD, and overall. The chart shows the number and percentage of patients in Clopidogrel and Aspirin groups, with corresponding hazard ratios and 95% confidence intervals indicating preference towards Clopidogrel Tablets or Aspirin.*

FDA Label Image

Label Image (Lbl500907467)

Label for CLOPIDOGREL 75 mg oral tablets, provided by A-S Medication Solutions. The label indicates each film-coated tablet contains 75 mg of clopidogrel bisulfate, equivalent to 75 mg of clopidogrel base. The package contains 90 tablets with storage instructions to keep at 77 degrees Fahrenheit. The label includes NDC 50090-7467-0 and directs users to see the package insert for dosage information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.